153 Therapeutics is a pre-clinical stage company spun out of UCSF and developing small-molecule therapeutics for Parkinson's Disease (PD) and other CNS disorders. Our core science is a based on targeting nuclear receptors in the CNS as a way to restore neurotransmitter signaling and to combat neuroinflammation and oxidative stress. Our lead compounds have recently demonstrated strong and statistically-significant efficacy in a PD animal model and are advancing through pre-clinical development and IND-enabling studies. A pipeline focused on PD and other neurodegenerative disorders (eg, Alzheimer’s, ALS, MS) is planned.